Codexis Appoints RNA Therapeutics Expert Arthur Levin, PhD, to Strategic Advisory Board

Codexis, Inc., a leader in enzymatic solutions for scalable therapeutics manufacturing, has appointed Arthur Levin, PhD, to its Strategic Advisory Board (SAB). Dr. Levin, a founding member of Avidity Biosciences and a recognized leader in RNA therapeutics, brings over 30 years of expertise in oligonucleotide drug development to support Codexis’ Enzyme Catalyzed Oligonucleotide (ECO) Synthesis™ platform.

“We are thrilled to have such a distinguished oligonucleotide leader as Art Levin join our SAB,” said Stefan Lutz, PhD, Senior Vice President of Research at Codexis. “With extensive experience in the development of numerous oligonucleotides, including the first approved antisense drugs and the first microRNA-targeted therapeutic in clinical trials, Art will provide invaluable guidance as we continue on our growth trajectory with the ECO Synthesis platform.”

Dr. Levin expressed enthusiasm for the role, stating, “I am excited to partner with Codexis as it expands the possibility of RNAi therapeutics through its groundbreaking enzymatic technologies. As someone who has been in the oligonucleotide business for decades, it is exciting to see momentum for the space increasing so drastically. I look forward to working with the management team and SAB to help usher Codexis through this next phase of growth.”

Dr. Levin has held key leadership roles, including Chief Scientific Officer at Avidity Biosciences, Executive Vice President of Research and Development at miRagen Therapeutics, and senior drug development positions at Ionis Pharmaceuticals and Santaris Pharmaceuticals. With more than 100 scientific publications and several highly cited reviews in the field, his contributions have significantly shaped the advancement of RNA-based medicines.

Codexis continues to drive innovation in enzymatic oligonucleotide manufacturing, and Dr. Levin’s expertise will play a crucial role in accelerating the company’s growth and impact in the RNA therapeutics space.